safety, efficacy, and pharmacokineticspharmacodynamics of daclizumab (anti-cd25) in patients with adult t-cell leukemialymphoma论文.pdfVIP

  • 11
  • 0
  • 约7.29万字
  • 约 12页
  • 2017-08-17 发布于湖北
  • 举报

safety, efficacy, and pharmacokineticspharmacodynamics of daclizumab (anti-cd25) in patients with adult t-cell leukemialymphoma论文.pdf

Clinical Immunology (2014) 155, 176–187 a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m C l i n i c a l I m m u n o l o g y w w w . e l s e v i e r . c o m / l o c a t e / y c l i m Safety, efficacy, and pharmacokinetics/ pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma☆ Jonathan L. Berkowitz a , 1, John E. Janik a , Donn M. Stewart a , Elaine S. Jaffe b , Maryalice Stetler-Stevenson

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档